ERS Congress 2026: key results and trends

Among patients who met guideline criteria, 57 (16.6%) in the placebo group died versus 33 (9.7%) in the nerandomilast 9 mg bid group (HR: 0.55 [0.36, 0.85]) and 31(9.1%) in the nerandomilast 18 mg bid group (HR: 0.54 [0.35, 0.84]).

Participants with 0 (n=109) or ≥1 (n=211) CMC had a longer time to a first clinical worsening event with sotatercept vs placebo (hazard ratio [95% CI]): 0 CMC 0.13 (0.04–0.43; P<0.0001); ≥1 CMCs 0.29 (0.16–0.54; P<0.0001).

The annualized rate of moderate/severe exacerbations was reduced with mepolizumab vs placebo by 22% (BEC ≥150 cells/µL) and 18% (≥300 cells/µL) in patients with GOLD 2 and similarly by 19% (BEC ≥150 cells/µL) and 24% (≥300 cells/µL) in those with GOLD 3+4.

The primary end point occurred in 27% of patients assigned to metoprolol and in 30% assigned to standard care (hazard ratio 0.87; 95% confidence interval (CI) 0.73-1.05, P = 0.14).

At Wk 24, more patients receiving dupilumab vs omalizumab achieved asthma remission (64.0% vs 40.5%, P<0.0001) and greater NPS improvements independent of asthma remission status.

Treatment-emergent adverse events (TEAEs) were similar (72.5%-76.5% CM326 vs 75% placebo), with no discontinuations or deaths.

Incidence of treatment-emergent adverse events (TEAEs) was 61.5% with lunsekimig vs 42.5% with pbo; common TEAEs (≥5%) were injection site reaction, viral upper respiratory tract infection, nasopharyngitis, epistaxis, ear pain, and increased creatine phosphokinase.

Treatment-emergent adverse event incidence was similar with verekitug (58–62%) vs PBO (66%).

The TRAE rate was 6.1% in the 1.5 mg group, lower than that of placebo (7.9%).

Daytime CC and cough bouts were also reduced vs PBO (–48.8% vs –18.6%, and –36.8% vs 17.9%, respectively).

At 3 months, AE-ILD progression-related mortality remained 0% in the CAStem Cell groups, significantly lower than in the placebo group (20%, P = 0.032).

The most common TEAE was upper respiratory tract infection (18.3% in 9MW1911 vs. 25.0% in placebo).